Prolight announces outcome in the rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
Prolight’s board and management increase their shareholdings
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Members […]
Prolight Diagnostics achieves ISO 13485 accreditation
Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, today announces that their subsidiary Psyros Diagnostics has gained accreditation to the industry standard ISO 13485, which sets out the requirements for a quality management system (QMS) specific to the medical devices industry. “The accreditation shows that our quality processes meet global quality requirements which is […]
Prolight Diagnostics shows proof of performance in whole blood
Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, has demonstrated that its single molecule detection system gives equivalent performance in whole blood compared to plasma, without having to separate the cells from the sample. “This is a very important breakthrough for our single molecule counting technology. We are not aware of any other single […]
Prolight Diagnostics publishes investor letter for October 2023
Prolight Diagnostics publishes an investor letter for October 2023. In the investor letter, an interview is given with Karl Bullen, COO at Prolight Diagnostics. Link to investor letters:https://prolightdx.com/en/mediaeng/investor-letters/ For further information, please contact:Prolight Diagnostics AB (publ)E-mail: info@prolightdx.comTelephone: +46 73 582 39 87Website: www.prolightdx.com/en/ About UsProlight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable […]
Prolight Diagnostics publishes investor letter for July 2023
Prolight Diagnostics publishes an investor letter for July 2023. In the investor letter, a first summary of the Congress Annual Scientific Meeting + Clinical Lab Expo in Anaheim, USA is given. Link to investor letters:https://prolightdx.com/en/mediaeng/investor-letters/ For further information, please contact:Prolight Diagnostics AB (publ)E-mail: ub@prolightdx.comTelephone: +46 73 582 39 87Website: www.prolightdx.com/en/ About UsProlight Diagnostics, together with […]
Prolight Diagnostics publishes investor letter for July 2023
Prolight Diagnostics publishes an investor letter for July 2023. In the investor letter, you can read about the launch of the company’s new website and that Prolight Diagnostics is now present at the 2023 AACC Annual Scientific Meeting + Clinical Lab Expo in the USA. Link to investor letters:https://prolightdx.com/en/mediaeng/investor-letters/ For further information, please contact:Prolight Diagnostics […]
Prolight Diagnostics showcases breakthrough POC technology at the AACC Annual Scientific Meeting & Clinical Lab Expo
Prolight Diagnostics (“Prolight”) announced today that it will showcase the company’s digital single molecule counting Point-of-Care (POC) system, with high-sensitive troponin capabilities, at the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo in Anaheim, CA, July 23–27. “For the first time we will showcase a concept of our point-of-care (POC) […]
Prolight Diagnostics shows proof-of-performance for high-sensitive troponin
Prolight Diagnostics (“Prolight”) today announces that its subsidiary Psyros Diagnostics (“Psyros”) has been able to demonstrate proof-of-performance on its single molecule detection system to reproducibly detect low levels of the troponin protein. These results pave the way for early detection and rule-out of heart attack, which could reduce healthcare costs and improve the quality of […]
Prolight Diagnostics submits patent applications for multiplex testing and enhancing dynamic range
Prolight Diagnostics (“Prolight”) today announces that the company’s subsidiary Psyros Diagnostics (“Psyros”) has submitted two priority patent applications covering various aspects of multiplexing capabilities to the Intellectual Property Office in Great Britain. The first application covers various aspects of multiplexing (i.e., detecting several different biomarkers at the same time on a single sample). By using […]
